Dose Escalation Study of TriN2755 in Advanced Solid Tumors and Sarcomas
Status:
Unknown status
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, parallel-group, two-center, safety, activity and pharmacokinetic study
of TriN 2755 given at increasing dose levels as intravenous infusions administered over 4
hours. The study is divided into two parts: Part I a dose escalation phase and Part II an
extension phase.
Phase:
Phase 1
Details
Lead Sponsor:
Trin Therapeutics GmbH
Collaborators:
Assign Data Management and Biostatistics GmbH Central European Society for Anticancer Drug Research University Hospital, Essen